Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.71 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747227 | 0.88 | HCAR2 (0.60) | MAOBPARP10NR4A2 | |
| SCHEMBL6901937 | 0.88 | HCAR2 (0.60) | MAOBPARP10NR4A2 | |
| SCHEMBL4427394 | 0.88 | MAOB (0.66) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL4425874 | 0.84 | MAOB (0.67) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL6634107 | 0.84 | PARP10 (0.68) | MAOBPARP10NR4A2MAOA | |
| SCHEMBL3503549 | 0.83 | MAOB (1.00) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL4425043 | 0.83 | MAOB (0.62) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL1534882 | 0.81 | MAOB (0.67) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL4423295 | 0.81 | MAOB (0.71) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL992837 | 0.81 | MAOB (1.00) | MAOBPARP10NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761480-B1 | MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885PARP10 1329/4885NR4A2 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.